

## Bundled Payments for Care Improvement (BPCI) Advanced Annual Check-in Questionnaire

[illegible]

1

7

### Purpose:

Participants' activities and barriers related to designing and implementing the BPCI Advanced Model

1

### Instructions:

The first part of the study was a pilot study. The purpose of the pilot study was to determine the feasibility of the study and to estimate the sample size required for the main study. The pilot study was conducted with 10 participants. The results of the pilot study showed that the study was feasible and that the sample size required for the main study was 100 participants.

The main study was conducted with 100 participants. The participants were recruited from a local community center. The participants were randomly assigned to two groups: the experimental group and the control group. The experimental group received the intervention, and the control group did not receive the intervention. The intervention was a 12-week program of physical activity and nutrition education. The participants in the experimental group were instructed to engage in 150 minutes of moderate-intensity physical activity per week and to consume a diet that was rich in fruits, vegetables, and whole grains. The participants in the control group were instructed to continue with their current level of physical activity and diet.

The primary outcome of the study was the change in body mass index (BMI) over the 12-week period. The secondary outcomes were the change in waist circumference, blood pressure, and blood sugar levels. The results of the study showed that the participants in the experimental group had a significantly greater reduction in BMI, waist circumference, blood pressure, and blood sugar levels compared to the participants in the control group.

The results of the study suggest that a 12-week program of physical activity and nutrition education can effectively reduce BMI, waist circumference, blood pressure, and blood sugar levels in a community-based population. These findings have important implications for the development of public health interventions aimed at reducing the risk of chronic diseases.

Diagram illustrating the location of the *rrd* gene on the *E. coli* genome. The genome is shown as a circular map with various genes labeled. The *rrd* gene is located on the right side of the map, between the *rrd* and *rrd* genes.

- 

[illegible]

- □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ d r r r  
□ □ □ □ □ □ □ □ r r r
- □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ r r r r  
“Open with”  
□ □ □ □ □ □ □ □ d □ □ □ □ □ r □ □ □ □ R □ d r r □ □ □ □  
dr □ □ d □ □ □ □ □ □ □



no later than **September 23, 2019 at 11:59PM ET** [Click here](#)  
 to download the [2019-2020](#) [2020-2021](#) [2021-2022](#) [2022-2023](#) [2023-2024](#) [2024-2025](#) [2025-2026](#) [2026-2027](#) [2027-2028](#) [2028-2029](#) [2029-2030](#) [2030-2031](#) [2031-2032](#) [2032-2033](#) [2033-2034](#) [2034-2035](#) [2035-2036](#) [2036-2037](#) [2037-2038](#) [2038-2039](#) [2039-2040](#) [2040-2041](#) [2041-2042](#) [2042-2043](#) [2043-2044](#) [2044-2045](#) [2045-2046](#) [2046-2047](#) [2047-2048](#) [2048-2049](#) [2049-2050](#) [2050-2051](#) [2051-2052](#) [2052-2053](#) [2053-2054](#) [2054-2055](#) [2055-2056](#) [2056-2057](#) [2057-2058](#) [2058-2059](#) [2059-2060](#) [2060-2061](#) [2061-2062](#) [2062-2063](#) [2063-2064](#) [2064-2065](#) [2065-2066](#) [2066-2067](#) [2067-2068](#) [2068-2069](#) [2069-2070](#) [2070-2071](#) [2071-2072](#) [2072-2073](#) [2073-2074](#) [2074-2075](#) [2075-2076](#) [2076-2077](#) [2077-2078](#) [2078-2079](#) [2079-2080](#) [2080-2081](#) [2081-2082](#) [2082-2083](#) [2083-2084](#) [2084-2085](#) [2085-2086](#) [2086-2087](#) [2087-2088](#) [2088-2089](#) [2089-2090](#) [2090-2091](#) [2091-2092](#) [2092-2093](#) [2093-2094](#) [2094-2095](#) [2095-2096](#) [2096-2097](#) [2097-2098](#) [2098-2099](#) [2099-2100](#) [2100-2101](#) [2101-2102](#) [2102-2103](#) [2103-2104](#) [2104-2105](#) [2105-2106](#) [2106-2107](#) [2107-2108](#) [2108-2109](#) [2109-2110](#) [2110-2111](#) [2111-2112](#) [2112-2113](#) [2113-2114](#) [2114-2115](#) [2115-2116](#) [2116-2117](#) [2117-2118](#) [2118-2119](#) [2119-2120](#) [2120-2121](#) [2121-2122](#) [2122-2123](#) [2123-2124](#) [2124-2125](#) [2125-2126](#) [2126-2127](#) [2127-2128](#) [2128-2129](#) [2129-2130](#) [2130-2131](#) [2131-2132](#) [2132-2133](#) [2133-2134](#) [2134-2135](#) [2135-2136](#) [2136-2137](#) [2137-2138](#) [2138-2139](#) [2139-2140](#) [2140-2141](#) [2141-2142](#) [2142-2143](#) [2143-2144](#) [2144-2145](#) [2145-2146](#) [2146-2147](#) [2147-2148](#) [2148-2149](#) [2149-2150](#) [2150-2151](#) [2151-2152](#) [2152-2153](#) [2153-2154](#) [2154-2155](#) [2155-2156](#) [2156-2157](#) [2157-2158](#) [2158-2159](#) [2159-2160](#) [2160-2161](#) [2161-2162](#) [2162-2163](#) [2163-2164](#) [2164-2165](#) [2165-2166](#) [2166-2167](#) [2167-2168](#) [2168-2169](#) [2169-2170](#) [2170-2171](#) [2171-2172](#) [2172-2173](#) [2173-2174](#) [2174-2175](#) [2175-2176](#) [2176-2177](#) [2177-2178](#) [2178-2179](#) [2179-2180](#) [2180-2181](#) [2181-2182](#) [2182-2183](#) [2183-2184](#) [2184-2185](#) [2185-2186](#) [2186-2187](#) [2187-2188](#) [2188-2189](#) [2189-2190](#) [2190-2191](#) [2191-2192](#) [2192-2193](#) [2193-2194](#) [2194-2195](#) [2195-2196](#) [2196-2197](#) [2197-2198](#) [2198-2199](#) [2199-2200](#) [2200-2201](#) [2201-2202](#) [2202-2203](#) [2203-2204](#) [2204-2205](#) [2205-2206](#) [2206-2207](#) [2207-2208](#) [2208-2209](#) [2209-2210](#) [2210-2211](#) [2211-2212](#) [2212-2213](#) [2213-2214](#) [2214-2215](#) [2215-2216](#) [2216-2217](#) [2217-2218](#) [2218-2219](#) [2219-2220](#) [2220-2221](#) [2221-2222](#) [2222-2223](#) [2223-2224](#) [2224-2225](#) [2225-2226](#) [2226-2227](#) [2227-2228](#) [2228-2229](#) [2229-2230](#) [2230-2231](#) [2231-2232](#) [2232-2233](#) [2233-2234](#) [2234-2235](#) [2235-2236](#) [2236-2237](#) [2237-2238](#) [2238-2239](#) [2239-2240](#) [2240-2241](#) [2241-2242](#) [2242-2243](#) [2243-2244](#) [2244-2245](#) [2245-2246](#) [2246-2247](#) [2247-2248](#) [2248-2249](#) [2249-2250](#) [2250-2251](#) [2251-2252](#) [2252-2253](#) [2253-2254](#) [2254-2255](#) [2255-2256](#) [2256-2257](#) [2257-2258](#) [2258-2259](#) [2259-2260](#) [2260-2261](#) [2261-2262](#) [2262-2263](#) [2263-2264](#) [2264-2265](#) [2265-2266](#) [2266-2267](#) [2267-2268](#) [2268-2269](#) [2269-2270](#) [2270-2271](#) [2271-2272](#)

M r d M r r d d d r  
r rd r M  
d d M

101

☐  
☐  
☐  
☐  
☐

☐  
☐  
☐  
☐

1

□ □ □ □

□ □ □ □ □

□ □ □ □ □

100

## Participant Profile

9

1001

## Care Redesign Plan

1001

□ r □ □ □ □ □ D □ □ □ □ r □ □ □

☐

☐

☐

□ □ □ □ □ □ □ □ □ □ □ □ □ □

**D** **r** **d** **d** **R**

☐  
☐  
☐  
☐  
☐

$\frac{1}{\sqrt{\pi}} \int_0^x e^{-t^2} dt = \frac{1}{\sqrt{\pi}} \left( x - \frac{x^3}{3} + \frac{x^5}{5} - \frac{x^7}{7} + \frac{x^9}{9} - \frac{x^{11}}{11} + \frac{x^{13}}{13} - \frac{x^{15}}{15} + \frac{x^{17}}{17} - \frac{x^{19}}{19} + \frac{x^{21}}{21} - \frac{x^{23}}{23} + \frac{x^{25}}{25} - \frac{x^{27}}{27} + \frac{x^{29}}{29} - \frac{x^{31}}{31} + \frac{x^{33}}{33} - \frac{x^{35}}{35} + \frac{x^{37}}{37} - \frac{x^{39}}{39} + \frac{x^{41}}{41} - \frac{x^{43}}{43} + \frac{x^{45}}{45} - \frac{x^{47}}{47} + \frac{x^{49}}{49} - \frac{x^{51}}{51} + \frac{x^{53}}{53} - \frac{x^{55}}{55} + \frac{x^{57}}{57} - \frac{x^{59}}{59} + \frac{x^{61}}{61} - \frac{x^{63}}{63} + \frac{x^{65}}{65} - \frac{x^{67}}{67} + \frac{x^{69}}{69} - \frac{x^{71}}{71} + \frac{x^{73}}{73} - \frac{x^{75}}{75} + \frac{x^{77}}{77} - \frac{x^{79}}{79} + \frac{x^{81}}{81} - \frac{x^{83}}{83} + \frac{x^{85}}{85} - \frac{x^{87}}{87} + \frac{x^{89}}{89} - \frac{x^{91}}{91} + \frac{x^{93}}{93} - \frac{x^{95}}{95} + \frac{x^{97}}{97} - \frac{x^{99}}{99} \right)$

[illegible]

## CEHRT Use

1. *To meet this criterion, at least 75 percent of eligible clinicians in each participating APM Entity group, or each hospital if hospitals are the APM Entities, to use CEHRT to document and communicate clinical care.*

1111



[illegible]

☐  
☐  
☐

$\frac{d}{dt} \left( \frac{1}{2} m v^2 + U(r) \right) = -\frac{dU}{dr} \cdot \frac{dr}{dt}$

□ □ □ □ □ □ □ □ □ □ □ □ □

## Partner Agreements

1. **Definition:** A **Discrete-Time Signal** is a function of a discrete variable, typically time, represented by a sequence of values. It is denoted by  $x[n]$ , where  $n$  is the discrete time index.

□ □ □ □ □

□□□ □□□□□□□□ r□□□□□□□□□□□□□□□□□□□ d□□□ r□□□ □□□□□□ □□□□□□□□□□ r□□□□□□□□□□ r□□□□□□□□□□ r□□□

☐

☐

☐

☐

☐

[illegible]

☐☐☐☐☐

[illegible]

- [illegible]

4.

$\frac{1}{n} \sum_{i=1}^n x_i = \bar{x}$

Diagram illustrating the structure of a DNA sequence. The sequence is represented by a horizontal bar divided into segments. The segments are labeled with letters: D, r, d, r. The segments are color-coded: D is blue, r is green, d is red, and r is green. The segments are arranged in a sequence: D, r, d, r. The segments are connected by lines, indicating a continuous sequence.

- □ □ □

□ □ □ □ □

□ □ □ □ □ □ □ □ □ □ □ □ □

1003

[illegible]

1

□ □ □ □ □



□□□□ □□□□ d □□ r □□□□□□□□ d r □□□□□□□□□□ r □ d the Participant's d □□□□□□□□□□  
□ □□□□□□□□□□□□□□□ r □□ r □□ rd □□□□□□□□□□□□□□□□ rr □□□□ □□□□□□

### Internal Cost Savings (ICS)

[illegible][illegible]

### Net Payment Reconciliation Amount (NPRA)

**D** **r** **R** **d** **d** **r**

**r** **r** **d** **d** [Performance Period 1: October 1, 2018 through June 30, 2019]

## Compliance Plan

- ## Waivers (Fraud & Abuse Waivers and Medicare Payment Policy Waivers)

Participant Profile Selection Does Not Limit Use of Waivers”

[illegible]

□ □ □

[illegible]

☐

☐

☐

[illegible]

-  

1001

[illegible]

333

☐ If you selected 'Yes' to ques and  
☐

☐

☐

☐

☐

☐

[illegible]

☐  
☐  
☐  
☐  
☐  
☐

[illegible]

-   
  


1000000

[illegible]

1000000

☐ If selected ‘Yes’ to question    
☐

[illegible]

□ □ □

☐ If selected 'Other' to question

□ □ □ □ □ □ □ □ □ □ □ □ □ □

□ □ □ □ □

9

□ □ □ □

[illegible]

1



[illegible][illegible]

5



## BPCI Advanced Impact





☐ If selected 'Yes' to either question 1 or 2, ☐ **d** ☐ **r** ☐

☐

□

□

1

5

1

☐☐☐ ☐

10



111

[illegible][illegible]

5

9







5

[illegible]

d

[illegible]

□ □ □ □ □ □ □ **R** □ □ □ □ □ □ □

☐ ☒ ☐ r ☐

[illegible]

## Document Submission



9

$\frac{d}{dt} \left( \frac{1}{r^2} \right) = -\frac{2}{r^3} \frac{dr}{dt}$

[illegible]

□

9



5



[illegible]

- ☐

☐

☐

☐

☐

## Self-disclosed Investigations or Sanctions

[illegible]

- □ □

2. I selected 'Yes' to the question "Do you agree to participate in the study?"
- I understand that my participation in the study is voluntary and that I may withdraw from the study at any time without penalty or loss of benefits to which I am entitled.
- Additional information is located under Article 13 of the [Participation Agreement](#).

- □ □ □ □ □ □

### Other Issues Not Previously Listed

[illegible]

-